Stomach Medicine Found to Cause Dementia

Stomach Medicine Found to Cause Dementia


  • Proton pump inhibitors (PPIs) are commonly used to treat gastro-esophageal reflux disorders (GERD) and ulcers.
  • A recent article published in JAMA Neurology has found that PPIs have been identified as being at risk for causing dementia.
  • Chiropractic physicians may discuss this complication with their patients and advise patients who may be candidates for alternative treatment for GERD and ulcers.



Medications that influence the risk of dementia in the elderly can be relevant for dementia prevention. Proton pump inhibitors (PPIs) are widely used for the dementiatreatment of gastrointestinal diseases but have also been shown to be potentially involved in cognitive decline.


To examine the association between the use of PPIs and the risk of incident dementia in the elderly.


We conducted a prospective cohort study using observational data from 2004 to 2011, derived from the largest German statutory health insurer, Allgemeine Ortskrankenkassen (AOK). Data on inpatient and outpatient diagnoses (coded by the German modification of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) and drug prescriptions (categorized according to the Anatomical Therapeutic Chemical Classification System) were available on a quarterly basis. Data analysis was performed from August to November 2015.


Prescription of omeprazole, pantoprazole, lansoprazole, esomeprazole, or rabeprazole.


The main outcome was a diagnosis of incident dementia coded by the German modification of the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. The association between PPI use and dementia was analyzed using time-dependent Cox regression. The model was adjusted for potential confounding factors, including age, sex, comorbidities, and polypharmacy.


A total of 73 679 participants 75 years of age or older and free of dementia at baseline were analyzed. The patients receiving regular PPI medication (n = 2950; mean [SD] age, 83.8 [5.4] years; 77.9% female) had a significantly increased risk of incident dementia compared with the patients not receiving PPI medication (n = 70 729; mean [SD] age, 83.0 [5.6] years; 73.6% female) (hazard ratio, 1.44 [95% CI, 1.36-1.52]; P < .001).


The avoidance of PPI medication may prevent the development of dementia. This finding is supported by recent pharmacoepidemiological analyses on primary data and is in line with mouse models in which the use of PPIs increased the levels of β-amyloid in the brains of mice. Randomized, prospective clinical trials are needed to examine this connection in more detail.


W Gomm, K von Holt, F Thomé, K Broich, W Maier, A Fink, G Doblhammer, B Haenisch.  Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 2016 Feb 15;[EPub Ahead of Print],


Comments are closed.